Establishment of a XXXX B-cell tumor in athymic @entity19 .

@entity1 @entity19 @entity5 @entity2109 @entity1492 @entity3
@entity1 B-cell @entity5 have been established in athymic, BALB/c @entity19 using the EBV-positive @entity2109 cell line Namalwa. One-hundred-one of 104 animals (97%) developed @entity5 10-14 days following s.c. injection of a mixture of 20 x 10(6) Namalwa and 5 X 10(6) irradiated @entity1 @entity1492 (HT-1080) cells. @entity5 developed at the site of injection and reached approximately 300 mm2 (product of cross-sectional diameters) after 21 days; no @entity3 were found. Histological analysis showed that @entity5 consisted solely of lymphoid cells. Immunofluorescence assays demonstrated that while 85% of the @entity5 cells retained reactivity with the monoclonal B-cell antibody BA-1, 96% retained reactivity with antibody BA-2 and 43% with BA-3. A similar reactivity profile was observed with cultured Namalwa cells. @entity5 were passaged serially 10 times without significant change in BA-1, BA-2, or BA-3 reactivity. Indirect immunofluorescence demonstrated that antibody BA-2 reached @entity5 cells within 2 h following i.p. injection; antigen modulation was not observed. These results demonstrate the suitability of this B-cell model for testing the in vivo efficacy and stability of anti-B-cell immunoconjugates.
